PMID- 27672078
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20181202
IS  - 1559-0267 (Electronic)
IS  - 1080-0549 (Print)
IS  - 1080-0549 (Linking)
VI  - 54
IP  - 3
DP  - 2018 Jun
TI  - Efficacy of Treatment of Non-hereditary Angioedema.
PG  - 412-431
LID - 10.1007/s12016-016-8585-0 [doi]
AB  - Non-hereditary angioedema (AE) with normal C1 esterase inhibitor (C1INH) can be 
      presumably bradykinin- or mast cell-mediated, or of unknown cause. In this 
      systematic review, we searched PubMed, EMBASE, and Scopus to provide an overview 
      of the efficacy of different treatment options for the abovementioned subtypes of 
      refractory non-hereditary AE with or without wheals and with normal C1INH. After 
      study selection and risk of bias assessment, 61 articles were included for data 
      extraction and analysis. Therapies were described for angiotensin-converting 
      enzyme inhibitor-induced AE (ACEi-AE), for idiopathic AE, and for AE with wheals. 
      Described treatments consisted of ecallantide, icatibant, C1INH, fresh frozen 
      plasma (FFP), tranexamic acid (TA), and omalizumab. Additionally, individual 
      studies for anti-vitamin K, progestin, and methotrexate were found. Safety 
      information was available in 26 articles. Most therapies were used off-label and 
      in few patients. There is a need for additional studies with a high level of 
      evidence. In conclusion, in acute attacks of ACEi-AE and idiopathic AE, treatment 
      with icatibant, C1INH, TA, and FFP often leads to symptom relief within 2 h, with 
      limited side effects. For prophylactic treatment of idiopathic AE and AE with 
      wheals, omalizumab, TA, and C1INH were effective and safe in the majority of 
      patients.
FAU - van den Elzen, Mignon
AU  - van den Elzen M
AUID- ORCID: 0000-0002-8796-2231
AD  - Division of Internal Medicine and Dermatology, University Medical Center Utrecht, 
      Utrecht, The Netherlands. melzen3@umcutrecht.nl.
AD  - Department of Dermatology and Allergology, University Medical Center Utrecht 
      (G02.124), PO Box 85.500, 3508 GA, Utrecht, The Netherlands. 
      melzen3@umcutrecht.nl.
FAU - Go, M F C L
AU  - Go MFCL
AD  - Division of Internal Medicine and Dermatology, University Medical Center Utrecht, 
      Utrecht, The Netherlands.
FAU - Knulst, A C
AU  - Knulst AC
AD  - Division of Internal Medicine and Dermatology, University Medical Center Utrecht, 
      Utrecht, The Netherlands.
FAU - Blankestijn, M A
AU  - Blankestijn MA
AD  - Division of Internal Medicine and Dermatology, University Medical Center Utrecht, 
      Utrecht, The Netherlands.
FAU - van Os-Medendorp, H
AU  - van Os-Medendorp H
AD  - Division of Internal Medicine and Dermatology, University Medical Center Utrecht, 
      Utrecht, The Netherlands.
FAU - Otten, H G
AU  - Otten HG
AD  - Laboratory of Translational Immunology, University Medical Center Utrecht, 
      Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Progestins)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 6T84R30KC1 (Tranexamic Acid)
RN  - 7PG89G35Q7 (icatibant)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Angioedema/*therapy
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Bradykinin/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Omalizumab/*therapeutic use
MH  - Progestins/therapeutic use
MH  - Tranexamic Acid/*therapeutic use
MH  - Treatment Outcome
PMC - PMC6002429
OTO - NOTNLM
OT  - Angioedema
OT  - Angiotensin-converting enzyme inhibitor
OT  - Idiopathic
OT  - Treatment
OT  - Wheals
COIS- CONFLICT OF INTEREST: M.T. van den Elzen has received speaker's fees from 
      Novartis. A.C. Knulst is a member of the national and international Novartis 
      Omalizumab Advisory Council and has received speaker's fees from Novartis and 
      sponsoring for scientific studies from Novartis and Pharming. The rest of the 
      authors declare that they have no relevant conflicts of interest. FUNDING: None.
EDAT- 2016/09/28 06:00
MHDA- 2018/10/12 06:00
PMCR- 2016/09/27
CRDT- 2016/09/28 06:00
PHST- 2016/09/28 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2016/09/28 06:00 [entrez]
PHST- 2016/09/27 00:00 [pmc-release]
AID - 10.1007/s12016-016-8585-0 [pii]
AID - 8585 [pii]
AID - 10.1007/s12016-016-8585-0 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2018 Jun;54(3):412-431. doi: 10.1007/s12016-016-8585-0.